Cilta-cel or Standard Care in Lenalidomide-Refractory Multiple Myeloma

F. San Miguel, Jesús; Dhakal, Binod; Yong, Kwee; Spencer, Andrew; Anguille, Sébastien; Mateos, María‐Victoria; Fernández de Larrea, Carlos; Martínez‐López, Joaquín; Moreau, Philippe; Touzeau, Cyrille; Leleu, Xavier; Avivi, Irit; Cavo, Michèle; Ishida, Tadao; Jin Kim, Seok; Roeloffzen, Wilfried; W.C.J. van de Donk, Niels; Dytfeld, Dominik; Sidana, Surbhi; J. Costa, Luciano; Oriol, Albert; Popat, Rakesh; Khan, Abdullah; C. Cohen, Yaël; Joy Ho, P.; E. Griffin, James; Lendvai, Nikoletta; Lonardi, Carolina; Slaughter, Ana; M. Schecter, Jordan; C. Jackson, Carolyn; Connors, Kaitlyn; Li, Katherine; Zudaire, Enrique; Chen, Diana; Gilbert, Jane; Yeh, Tzu‐Min; Nagle, Sarah; Florendo, Erika; Pacaud, Lida; Patel, Nitin; J. Harrison, Simon; Einsele, Hermann

doi:10.1056/nejmoa2303379

Public

Cilta-cel or Standard Care in Lenalidomide-Refractory Multiple Myeloma

Published in New England Journal of Medicine • Jun 5, 2023

Authors:

Jesús F. San Miguel

Binod Dhakal

Kwee Yong

Abstract

BACKGROUND: Ciltacabtagene autoleucel (cilta-cel), a B-cell maturation antigen (BCMA)-directed CAR T-cell therapy, is effective in heavily pretreated patients with relapsed or refractory multiple myeloma. We investigated cilta-cel in earlier treatment lines in patients with lenalidomide-refractory d...

Subject

Lenalidomide

Multiple myeloma

Refractory (planetary science)

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!